Spero Therapeutics, Inc. (SPRO)

In October 2025, Phase 3 trial results for tebipenem HBr were presented. In November 2025, Spero reported a net loss of $7.4 million and revenue of $5.4 million for Q3 2025. In December 2025, GSK resubmitted the NDA for tebipenem HBr, triggering a $25 million milestone payment to Spero. In February 2026, the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, and insider selling activity was reported. In March 2026, Spero reported a Q4 2025 net income of $31.5 million and a full-year net income of $8.6 million, with Q4 revenue totaling $41.3 million and full-year revenue at $66.8 million, leading to a mild stock decline. As of April 7, 2026, the stock price had surpassed its 50-day moving average, increasing by 305.14% over the past year, with a recent 10-day change of 12.66% and a 3.96% decrease on April 10, 2026.

Information regarding demand seasonality for Spero Therapeutics, Inc.'s products is not readily available. Demand is likely driven by disease prevalence, treatment guidelines, and market access rather than typical seasonal consumer patterns.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Cambridge, Massachusetts, focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Their pipeline includes Tebipenem HBr, an oral carbapenem-class antibiotic in Phase 3 development for complicated urinary tract infections; SPR720, an oral antimicrobial agent for nontuberculous mycobacterial pulmonary disease; and SPR206, an IV-administered antibiotic for MDR Gram-negative bacterial infections.

Spero Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. The company has a license agreement with Meiji Seika Pharma Co., Ltd. for tebipenem HBr in certain Asian territories. Everest Medicines holds rights to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries.

Spero Therapeutics' reputation was impacted by past disclosures concerning tebipenem HBr. In January 2026, the SEC settled cease-and-desist proceedings against two former executives for allegedly issuing misleading statements about the FDA's evaluation of tebipenem HBr in 2022, resulting in civil penalties. A proposed class-action lawsuit concerning similar statements was dismissed in October 2024, but highlighted past allegations of fraudulent intent.

Spero Therapeutics, Inc. has a diverse ownership structure, with approximately 32.71% held by Institutional Investors, 5.32% by Insiders, and 61.96% by Public Companies and Individual Investors. Major institutional shareholders include Glaxosmithkline Plc, Pfizer Inc, Vanguard Group Inc, Renaissance Technologies Llc, Alphabet Inc., Anson Funds Management LP, Geode Capital Management, Llc, BlackRock, Inc., Citadel Advisors Llc, Two Sigma Investments, Lp, Point72 Asset Management, L.P., Texas Yale Capital Corp., Cullen/frost Bankers, Inc., SBI Securities Co., Ltd., and State Street Global Advisors, Inc.